DURECT to Participate in Upcoming Healthcare Conferences

           DURECT to Participate in Upcoming Healthcare Conferences

PR Newswire

CUPERTINO, Calif., Nov. 13, 2012

CUPERTINO, Calif., Nov. 13, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq:
DRRX) announced today that management is scheduled to present at two upcoming
healthcare conferences.

  oJames E. Brown, President and CEO, will present at the Credit Suisse 2012
    Healthcare Conference on Thursday, November 15 at 10:00 a.m. Mountain Time
    (12:00 Noon Eastern). The conference is being held at the Arizona
    Biltmore in Phoenix. A live audio webcast of the presentation will be
    available by accessing
    http://cc.talkpoint.com/cred001/111412a_am/?entity=82_F0ON47N.
  oJames E. Brown, President and CEO, will also present at the 24^th Annual
    Piper Jaffray Healthcare Conference on Tuesday, November 27 at 2:10 p.m.
    Eastern Time. The conference is being held at the New York Palace in New
    York. A live audio webcast of the presentation will be available by
    accessing http://www.media-server.com/m/p/etvfkg7z.

A live audio webcast of these presentations will also be available by
accessing DURECT's homepage at www.durect.com and clicking "Investor
Relations." If you are unable to participate during the live webcast, the
call will be archived on DURECT's website under Audio Archive in the "Investor
Relations" section.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

About DURECT Corporation

DURECT is a specialty pharmaceuticalcompany developing innovative drugs for
pain and other chronic diseases, with late-stage development programs
including REMOXY^®, POSIDUR^™, ELADUR^®, and TRANSDUR^®-Sufentanil. DURECT's
proprietaryoral, transdermal and injectable depot delivery technologies
enable new indications and superior clinical/commercial attributes such as
abuse deterrence, improved convenience, compliance, efficacy and safety for
small molecule and biologic drugs. For more information, please visit
www.durect.com.

NOTE: POSIDUR^™, SABER^™, ORADUR^®, TRANSDUR^®, ELADUR^™ and DURIN^® are
trademarks of DURECT Corporation. Other referenced trademarks belong to their
respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for commercialization
by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

Website: http://www.durect.com
Contact: Matthew J. Hogan, Chief Financial Officer, DURECT, +1-408-777-4936
 
Press spacebar to pause and continue. Press esc to stop.